Basilea Pharmaceutica’s Toctino(R) (alitretinoin) Receives First National Marketing Authorization in the UK

Marketwire -- Basel, Switzerland, September 8, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.

MORE ON THIS TOPIC